Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasm Metastasis 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1

Interventions

Gemcitabine 45Cisplatin 34Oxaliplatin 23Capecitabine 17Fluorouracil 13Leucovorin 12pembrolizumab 11lenvatinib 11durvalumab 10S 1 (combination) 10Irinotecan 10Bevacizumab 9apatinib 7Nivolumab 7tremelimumab 6Trastuzumab 5envafolimab 4atezolizumab 4Injections 4Docetaxel 4trametinib 3titanium silicide 3tislelizumab 3irinotecan sucrosofate 3camrelizumab 3Radiotherapy 3Drug Therapy 3zanidatamab 2toripalimab 2surufatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Biliary Tract Neoplasms × merestinib × Clear all
NCT02711553 2025-08-03

A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer

Eli Lilly and Company

Phase 2 Active not recruiting
309 enrolled 22 charts
Gastrointestinal

Biliary Tract Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡